Study on the mechanism of platinum resistance in ovarian cancer

Ovarian cancer is the third most lethal gynecological malignancy with the third highest incidence rate. It is characterized by complex histopathology, high malignancy and poor survival prognosis. Although there are many subtypes of ovarian cancer, the treatment for ovarian cancer is still relatively limited, mainly consisting of tumor cell reduction surgery and combination chemotherapy based on platinum and paclitaxel. Platinum based drugs are currently the first-line anti-tumor chemotherapy drugs for ovarian cancer. Although ovarian cancer is considered a platinum sensitive tumor with a high response rate to first-line conventional treatment, 75% of advanced patients still metastasize, relapse, and eventually develop resistance, resulting in poor long-term survival rates. Drug resistance and recurrence remain bottlenecks in the treatment of ovarian cancer, and clinical doctors urgently need new treatment plans that can effectively prolong the interval of platinum based chemotherapy and delay the recurrence of ovarian cancer. Therefore, in-depth research on the mechanism of drug resistance in ovarian cancer, identification of new drug resistance targets, and development of new effective treatment strategies are the urgent challenges that need to be overcome for ovarian cancer to move towards precision treatment. Based on this research background, the Illumina Hiseq 3000 platform was used to compare cancer tissue samples from 3 platinum sensitive and 5 platinum resistant high-grade serous ovarian cancer patients through high-throughput sequencing. In order to further investigate the mechanism of platinum resistance in ovarian cancer.